(Q37195539)

18 August 2017

1 reference

title

HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options (English)

1 reference

HIV-associated lipodystrophy

18 August 2017

0 references

1 reference

Munir Pirmohamed

7

0 references

author name string

Jane E Mallewa

1

1 reference

18 August 2017

Edmund Wilkins

2

1 reference

18 August 2017

Javier Vilar

3

1 reference

18 August 2017

Macpherson Mallewa

4

1 reference

18 August 2017

Dominic Doran

5

1 reference

18 August 2017

David Back

6

1 reference

18 August 2017

language of work or name

English

0 references

publication date

18 June 2008

1 reference

Journal of Antimicrobial Chemotherapy

18 August 2017

published in

1 reference

18 August 2017

volume

62

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

648-660

1 reference

Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Adiponectin: action, regulation and association to insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

RETRACTED: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Regulation of adipocytokines and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Obesity, adiponectin and vascular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor gamma, CREB-binding protein, and adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Diet-induced insulin resistance in mice lacking adiponectin/ACRP30

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Disruption of adiponectin causes insulin resistance and neointimal formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Monocyte chemoattractant protein-1 and atherosclerosis: is there room for an additional biomarker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Monocyte chemoattractant protein-1--a major contributor to the inflammatory process associated with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Monocyte chemoattractant protein 1 in obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Monocyte chemoattractant protein-1 in subcutaneous abdominal adipose tissue: characterization of interstitial concentration and regulation of gene expression by insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Leptin-replacement therapy for lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Trends in diagnostic testing following a national guideline for evaluation of dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Effectiveness of subcutaneous growth hormone in HIV-1 patients with moderate to severe facial lipoatrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Metformin: new understandings, new uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN251

21 January 2018

Identifiers

DOI

10.1093/JAC/DKN251

1 reference

18 August 2017

1 reference